Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company focused on redefining solid tumor cancer treatment with cell therapy, has announced it will release its Q2 2024 financial results and business updates on Monday, August 12, 2024, before US markets open. The company will host a live webcast at 8:00 a.m. EDT (1:00 p.m. BST) on the same day to discuss the results.
Investors can access the press release on Adaptimmune's corporate website, and join the webcast at https://www.gowebcasting.com/13404. For those preferring to call in, the numbers are +1-844-763-8274 (US/Canada) or +1-647-484-8814 (International). Participants are advised to dial in 10 minutes before the scheduled start time.
Adaptimmune Therapeutics plc (Nasdaq: ADAP), un'azienda focalizzata sulla ridefinizione del trattamento del cancro ai tumori solidi attraverso la terapia cellulare, ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2024 e aggiornamenti aziendali il lunedì 12 agosto 2024, prima dell'apertura dei mercati negli Stati Uniti. L'azienda ospiterà un webcast dal vivo alle 8:00 EDT (1:00 p.m. BST) lo stesso giorno per discutere i risultati.
Gli investitori possono accedere al comunicato stampa sul sito web aziendale di Adaptimmune e partecipare al webcast all'indirizzo https://www.gowebcasting.com/13404. Per coloro che preferiscono partecipare telefonicamente, i numeri sono +1-844-763-8274 (USA/Canada) o +1-647-484-8814 (internazionale). I partecipanti sono invitati a chiamare 10 minuti prima dell'orario di inizio programmato.
Adaptimmune Therapeutics plc (Nasdaq: ADAP), una empresa enfocada en redefinir el tratamiento del cáncer de tumores sólidos mediante terapia celular, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 y actualizaciones comerciales el lunes 12 de agosto de 2024, antes de la apertura de los mercados en EE. UU. La empresa realizará un webcast en vivo a las 8:00 a.m. EDT (1:00 p.m. BST) el mismo día para discutir los resultados.
Los inversores pueden acceder al comunicado de prensa en el sitio web corporativo de Adaptimmune y unirse al webcast en https://www.gowebcasting.com/13404. Para aquellos que prefieren llamar, los números son +1-844-763-8274 (EE. UU./Canadá) o +1-647-484-8814 (internacional). Se aconseja a los participantes que llamen 10 minutos antes de la hora de inicio programada.
Adaptimmune Therapeutics plc (Nasdaq: ADAP)는 세포 치료를 통해 고형 종양 암 치료를 재정의하는 데 초점을 맞춘 회사로, 2024년 2분기 재무 결과 및 사업 업데이트를 2024년 8월 12일 월요일에 미국 시장이 열리기 전에 발표할 것이라고 발표했습니다. 회사는 같은 날 오전 8시 EDT (오후 1시 BST)에 결과를 논의하기 위한 실시간 웹 세미나를 개최할 예정입니다.
투자자들은 Adaptimmune의 기업 웹사이트에서 보도자료에 접근할 수 있으며, https://www.gowebcasting.com/13404에서 웹 세미나에 참여할 수 있습니다. 전화로 참여를 선호하는 분들은 +1-844-763-8274 (미국/캐나다) 또는 +1-647-484-8814 (국제)를 이용하면 됩니다. 참가자들은 예정된 시작 시간보다 10분 전에 전화할 것을 권장합니다.
Adaptimmune Therapeutics plc (Nasdaq: ADAP), une entreprise axée sur la redéfinition du traitement du cancer des tumeurs solides par la thérapie cellulaire, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 et mises à jour commerciales le lundi 12 août 2024, avant l'ouverture des marchés aux États-Unis. L'entreprise organisera un webinaire en direct à 8h00 EDT (13h00 BST) le même jour pour discuter des résultats.
Les investisseurs peuvent accéder au communiqué de presse sur le site internet de l'entreprise Adaptimmune et rejoindre le webinaire à l'adresse https://www.gowebcasting.com/13404. Pour ceux qui préfèrent se connecter par téléphone, les numéros sont +1-844-763-8274 (États-Unis/Canada) ou +1-647-484-8814 (international). Les participants sont invités à composer le numéro 10 minutes avant l'heure de début prévue.
Adaptimmune Therapeutics plc (Nasdaq: ADAP), ein Unternehmen, das sich darauf konzentriert, die Behandlung von soliden Tumoren mittels Zelltherapie neu zu definieren, hat bekannt gegeben, dass es am Montag, den 12. August 2024, vor der Eröffnung der US-Märkte seine finanziellen Ergebnisse für das zweite Quartal 2024 sowie Unternehmensupdates veröffentlichen wird. Das Unternehmen wird am selben Tag um 8:00 Uhr EDT (13:00 Uhr BST) ein Live-Webcast veranstalten, um die Ergebnisse zu besprechen.
Investoren können die Pressemitteilung auf der Unternehmenswebsite von Adaptimmune einsehen und am Webcast unter https://www.gowebcasting.com/13404 teilnehmen. Für diejenigen, die lieber anrufen möchten, sind die Nummern +1-844-763-8274 (USA/Kanada) oder +1-647-484-8814 (international) verfügbar. Es wird empfohlen, 10 Minuten vor dem geplanten Beginn anzurufen.
- None.
- None.
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 5, 2024) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the second quarter ended June 30, 2024, before the US markets open on Monday, August 12, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT (1:00 p.m. BST) that same day.
The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/13404. Call in information is as follows:
+1-844-763-8274 (US or Canada) or +1-647-484-8814 (International). Callers should dial in 10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on designing, developing, and delivering cell therapies to transform the lives of people with cancer. The Company's unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contact
Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
M : +1 215 460 8920
Juli.Miller@adaptimmune.com
Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218819
FAQ
When will Adaptimmune (ADAP) report its Q2 2024 financial results?
What time is Adaptimmune's (ADAP) Q2 2024 earnings webcast scheduled for?
How can investors access Adaptimmune's (ADAP) Q2 2024 earnings call?
What is Adaptimmune's (ADAP) primary focus in cancer treatment?
